PASG Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	39 303.00
Average Volume	357 870
Market Cap	76.40M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.670
ATR14	$0.0110 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Borthwick Kathleen	Buy	227 000	Employee Stock Option (right to buy)
2024-03-15	Forman Mark S	Buy	203 000	Employee Stock Option (right to buy)
2024-03-15	Chou William	Buy	575 000	Employee Stock Option (right to buy)
2024-03-15	Cale Edgar B.	Buy	203 000	Employee Stock Option (right to buy)
2024-02-10	Borthwick Kathleen	Buy	4 000	Common Stock

INSIDER POWER
82.30
Last 96 transactions
Buy: 8 238 559 \| Sell: 441 732

Volume Correlation

Long: -0.38 (neutral)

Short: 0.09 (neutral)

Signal:(52.925) Neutral

Passage Bio Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Passage Bio Inc Correlation - Currency/Commodity

-0.03
( neutral )

-0.60
( weak negative )

0.00
( neutral )

-0.71
( moderate negative )

0.51
( weak )

0.05
( neutral )

Passage Bio Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.72M (0.00 %)
EPS:	$-1.860

Q4	2023
Revenue:	$0
Gross Profit:	$-807 000 (0.00 %)
EPS:	$-0.310

Q3	2023
Revenue:	$0
Gross Profit:	$-1.00M (0.00 %)
EPS:	$-0.490

Q2	2023
Revenue:	$0
Gross Profit:	$-978 000 (0.00 %)
EPS:	$-0.440

Financial Reports:

No articles found.

Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.